US5380738A
(en)
*
|
1993-05-21 |
1995-01-10 |
Monsanto Company |
2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
|
US6090834A
(en)
*
|
1993-05-21 |
2000-07-18 |
G.D. Searle & Co. |
Substituted oxazoles for the treatment of inflammation
|
US6613789B2
(en)
|
1994-07-28 |
2003-09-02 |
G. D. Searle & Co. |
Heterocyclo-substituted imidazoles for the treatment of inflammation
|
US5616601A
(en)
*
|
1994-07-28 |
1997-04-01 |
Gd Searle & Co |
1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
|
JP2636819B2
(ja)
*
|
1994-12-20 |
1997-07-30 |
日本たばこ産業株式会社 |
オキサゾール系複素環式芳香族化合物
|
JP3181190B2
(ja)
*
|
1994-12-20 |
2001-07-03 |
日本たばこ産業株式会社 |
オキサゾール誘導体
|
AU5860396A
(en)
*
|
1995-05-19 |
1996-11-29 |
G.D. Searle & Co. |
Substituted oxazoles for the treatment of inflammation
|
AU5886296A
(en)
|
1995-06-02 |
1996-12-18 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
|
US5643933A
(en)
*
|
1995-06-02 |
1997-07-01 |
G. D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6515014B2
(en)
|
1995-06-02 |
2003-02-04 |
G. D. Searle & Co. |
Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6512121B2
(en)
*
|
1998-09-14 |
2003-01-28 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
WO1996041645A1
(en)
*
|
1995-06-12 |
1996-12-27 |
G.D. Searle & Co. |
Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
DE69635048T2
(de)
*
|
1995-06-12 |
2006-02-16 |
G.D. Searle & Co. |
Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
|
US6593361B2
(en)
|
1995-07-19 |
2003-07-15 |
Merck & Co Inc |
Method of treating colonic adenomas
|
US5968974A
(en)
|
1995-07-19 |
1999-10-19 |
Merck & Co., Inc. |
Method of treating colonic adenomas
|
EP0889033B1
(de)
|
1995-09-29 |
2003-01-08 |
Shionogi & Co., Ltd. |
Alpha-substituierte heterozyklische benzylderivate, zwischenverbindungen zu ihrer herstellung und pestizide die diese als aktiver bestandteil enthalten
|
WO1997014679A2
(en)
*
|
1995-10-17 |
1997-04-24 |
G.D. Searle & Co. |
Method of detecting cyclooxygenase-2
|
JP2001506574A
(ja)
*
|
1996-02-13 |
2001-05-22 |
ジー.ディー.サール アンド カンパニー |
シクロオキシゲナーゼ―2阻害剤およびロイコトリエンa4ヒドロラーゼ阻害剤を含有する免疫抑制効果をもつ配合物
|
ES2243978T3
(es)
|
1996-02-13 |
2005-12-01 |
G.D. SEARLE & CO. |
Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
|
ES2169351T3
(es)
|
1996-02-13 |
2002-07-01 |
Searle & Co |
Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
|
ES2125161B1
(es)
*
|
1996-03-21 |
1999-11-16 |
Grupo Farmaceutico Almirall S |
Nuevos derivados de 2-(3h)-oxazolona.
|
US5908858A
(en)
*
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
NZ331542A
(en)
*
|
1996-04-12 |
1999-07-29 |
Searle & Co |
Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors and salts thereof that are useful in treating inflammation and inflammation-related disorders
|
US6677364B2
(en)
*
|
1998-04-20 |
2004-01-13 |
G.D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5945538A
(en)
*
|
1996-06-28 |
1999-08-31 |
American Cyanamid Company |
Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
|
US5750726A
(en)
*
|
1996-06-28 |
1998-05-12 |
American Cyanamid Company |
Process for the manufacture of 2-aryl-5-perfluoroalkylpyrrole derivatives and intermediates useful therefor
|
US5777132A
(en)
*
|
1996-06-28 |
1998-07-07 |
American Cyanamid Company |
Process for the manufacture of 2-aryl-5 perfluoroalkylpyrrole derivatives
|
US5925773A
(en)
*
|
1996-06-28 |
1999-07-20 |
American Cyanamid Company |
Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use thereof in the manufacture of insecticidal arylpyrroles
|
FR2753449B1
(fr)
*
|
1996-09-13 |
1998-12-04 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
|
SK284788B6
(sk)
|
1996-10-15 |
2005-11-03 |
G. D. Searle & Co. |
Použitie inhibítorov cyklooxygenázy-2 pri liečení a prevencii neoplázie
|
GEP20022812B
(en)
*
|
1997-04-18 |
2002-10-25 |
Searle & Co |
Using Cyclooxygenase-2 Inhibitors for Preparing Medicinal Means to Prevent Cardiovascular Disorders Connected with Inflammation Processes and Pharmaceutical Compositions Containing These Inhibitors
|
ES2131015B1
(es)
*
|
1997-09-12 |
2000-03-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de 2-(3h)-oxazolona, procedimientos para su preparacion y su empleo en composiciones farmaceuticas.
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
US6887893B1
(en)
*
|
1997-12-24 |
2005-05-03 |
Sankyo Company, Limited |
Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
|
IT1303672B1
(it)
|
1998-07-28 |
2001-02-23 |
Nicox Sa |
Sali nitrati di farmaci attivi nei disordini ossei
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US6649645B1
(en)
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US20010024664A1
(en)
*
|
1999-03-19 |
2001-09-27 |
Obukowicz Mark G. |
Selective COX-2 inhibition from edible plant extracts
|
FR2800373B1
(fr)
*
|
1999-10-27 |
2001-12-07 |
Oreal |
Procede de preparation d'oxazoles trisubstitues
|
PT1175214E
(pt)
*
|
1999-12-08 |
2005-04-29 |
Pharmacia Corp |
Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
|
IL150368A0
(en)
|
1999-12-23 |
2002-12-01 |
Nitromed Inc |
Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
|
DE10001166A1
(de)
|
2000-01-13 |
2001-07-19 |
Merckle Gmbh |
Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
|
WO2001081332A2
(en)
*
|
2000-04-25 |
2001-11-01 |
Pharmacia Corporation |
2-fluorobenzenesulfonyl compounds for the treatment of inflammation
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
US20020128267A1
(en)
*
|
2000-07-13 |
2002-09-12 |
Rebanta Bandyopadhyay |
Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
|
CN100488500C
(zh)
*
|
2000-07-20 |
2009-05-20 |
劳拉斯有限公司 |
Cox-2抑制剂预防免疫缺陷的用途
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
AU2001285334A1
(en)
*
|
2000-08-29 |
2002-03-13 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
JP2004529079A
(ja)
*
|
2000-12-15 |
2004-09-24 |
ファルマシア・コーポレーション |
植物抽出物による選択的cox−2阻害
|
WO2002047707A2
(en)
*
|
2000-12-15 |
2002-06-20 |
Pharmacia Corporation |
Selective cox-2 inhibition from non-edible plant extracts
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
CA2435350A1
(en)
*
|
2001-02-02 |
2002-08-15 |
Pharmacia Corporation |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
|
US7695736B2
(en)
|
2001-04-03 |
2010-04-13 |
Pfizer Inc. |
Reconstitutable parenteral composition
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
ATE445838T1
(de)
|
2001-07-25 |
2009-10-15 |
Raptor Pharmaceutical Inc |
Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
JP4391825B2
(ja)
|
2001-12-06 |
2009-12-24 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
US20040126438A1
(en)
*
|
2001-12-13 |
2004-07-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from plant extracts
|
US20040062823A1
(en)
*
|
2001-12-13 |
2004-04-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from non-edible plant extracts
|
TW562937B
(en)
*
|
2002-03-26 |
2003-11-21 |
Nanya Technology Corp |
Method for fast determining defect type of word line
|
US7329401B2
(en)
*
|
2002-04-15 |
2008-02-12 |
The Regents Of The University Of California |
Cyclooxygenase-2 selective agents useful as imaging probes and related methods
|
PL373523A1
(en)
*
|
2002-04-22 |
2005-09-05 |
Pfizer Products Inc. |
Indol-2-ones as selective inhibitors of cyclooxygenase-2
|
WO2003095623A2
(en)
*
|
2002-05-10 |
2003-11-20 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
|
US20030225054A1
(en)
*
|
2002-06-03 |
2003-12-04 |
Jingwu Duan |
Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
|
AU2003247622A1
(en)
*
|
2002-06-27 |
2004-01-19 |
Nitromed, Inc. |
Cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
AU2003279622A1
(en)
|
2002-06-28 |
2004-01-19 |
Nitromed, Inc. |
Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
|
JP2005535657A
(ja)
*
|
2002-07-02 |
2005-11-24 |
ファルマシア・コーポレーション |
シクロオキシゲナーゼ−2選択阻害剤及び血栓溶解剤の血管閉塞イベントの治療又は予防への使用
|
AU2003303041B2
(en)
|
2002-12-13 |
2008-07-24 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
CN1726018A
(zh)
*
|
2002-12-19 |
2006-01-25 |
法玛西雅公司 |
使用环加氧酶-2选择性抑制剂或环加氧酶-2抑制剂联合抗病毒剂治疗疱疹病毒感染的方法和组合物
|
US20040171664A1
(en)
*
|
2002-12-20 |
2004-09-02 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
TW200505446A
(en)
*
|
2003-01-17 |
2005-02-16 |
Fuj Isawa Pharmaceutical Co Ltd |
Inhibitor of cox
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
ATE342722T1
(de)
*
|
2003-05-07 |
2006-11-15 |
Osteologix As |
Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
|
PL2266584T3
(pl)
*
|
2003-05-07 |
2013-02-28 |
Osteologix As |
Kompozycja ze strontem i witaminą D do profilaktyki i/lub leczenia chorób chrząstki i/lub kości
|
US20050065154A1
(en)
*
|
2003-06-24 |
2005-03-24 |
Pharmacia Corporation |
Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents
|
AU2004266705A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
AU2004270162B2
(en)
*
|
2003-08-28 |
2010-05-13 |
Nicox S.A. |
Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
|
US7067159B2
(en)
*
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
US7070816B2
(en)
*
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
AU2005207037A1
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
WO2005079808A1
(en)
|
2004-01-22 |
2005-09-01 |
Pfizer Limited |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
FR2866340B1
(fr)
|
2004-02-13 |
2006-11-24 |
Sanofi Synthelabo |
Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
|
KR101347830B1
(ko)
|
2004-05-23 |
2014-01-07 |
에이치엠아이, 인코포레이티드 |
테라뮤틴 조절물질
|
PE20060362A1
(es)
*
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de oxazol como moduladores de ppar
|
AU2005262373B2
(en)
|
2004-07-01 |
2011-03-17 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
US7622142B2
(en)
*
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
AU2005304770A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Nicox S.A. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
WO2006055542A2
(en)
*
|
2004-11-15 |
2006-05-26 |
Nitromed, Inc. |
Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
|
WO2006078995A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nitromed, Inc. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
JP2008530226A
(ja)
*
|
2005-02-16 |
2008-08-07 |
ニトロメッド インコーポレーティッド |
抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
EP1858863A1
(de)
*
|
2005-02-28 |
2007-11-28 |
Nitromed, Inc. |
Stickstoffmonoxid-verstärkende gruppen enthaltende cardiovaskuläre verbindungen, zusammensetzungen und anwendungsverfahren
|
WO2006099058A2
(en)
*
|
2005-03-09 |
2006-09-21 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
AU2006228869A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Astion Pharma A/S |
Oxaprozin or a closely related compound for the treatment of eczema
|
US20060222671A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Astion Development A/S |
Dermatological compositions and salts for the treatment of dermatological diseases
|
CA2789262C
(en)
|
2005-04-28 |
2016-10-04 |
Proteus Digital Health, Inc. |
Pharma-informatics system
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
EP1915157A4
(de)
*
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
|
PE20070335A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
EP1942909A4
(de)
*
|
2005-10-04 |
2010-01-06 |
Nitromed Inc |
Verfahren zur behandlung von atemwegserkrankungen
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
JP2009523408A
(ja)
*
|
2005-11-23 |
2009-06-25 |
ジェラルド・エム・ハウシー |
タンパク質モジュレーターを同定、合成、最適化および解析する化合物群および方法群
|
WO2007075541A2
(en)
*
|
2005-12-20 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
US20090062302A1
(en)
|
2006-01-24 |
2009-03-05 |
Buser-Doepner Carolyn A |
Jak2 Tyrosine Kinase Inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8067414B2
(en)
*
|
2006-03-29 |
2011-11-29 |
Nicox S.A. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
WO2008033466A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Combinatorx (Singapore) Pre. Ltd. |
Compositions and methods for treatment of viral diseases
|
MX2009002893A
(es)
|
2006-09-18 |
2009-07-10 |
Raptor Pharmaceutical Inc |
Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
|
JP5489333B2
(ja)
|
2006-09-22 |
2014-05-14 |
メルク・シャープ・アンド・ドーム・コーポレーション |
脂肪酸合成阻害剤を用いた治療の方法
|
US20080208179A1
(en)
*
|
2006-10-26 |
2008-08-28 |
Reliant Technologies, Inc. |
Methods of increasing skin permeability by treatment with electromagnetic radiation
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
JP5308350B2
(ja)
|
2006-12-22 |
2013-10-09 |
レコルダーティ アイルランド リミテッド |
α2δリガンドおよびNSAIDを用いた下部尿路機能障害の併用療法
|
PL2336120T3
(pl)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
|
CN101626787A
(zh)
*
|
2007-01-19 |
2010-01-13 |
马林克罗特公司 |
诊断的和治疗的环氧合酶-2结合配体
|
BRPI0808523A2
(pt)
|
2007-03-01 |
2014-08-19 |
Novartis Vaccines & Diagnostic |
Inibidores de pim cinase e métodos de seu uso
|
KR20100017866A
(ko)
|
2007-05-21 |
2010-02-16 |
노파르티스 아게 |
Csf-1r 억제제, 조성물 및 사용 방법
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US20090011060A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Peter Koepke |
Campsiandra angustifolia extract and methods of extracting and using such extract
|
US20090017140A1
(en)
*
|
2007-07-09 |
2009-01-15 |
Peter Koepke |
Maytenus abenfolia extract and methods of extracting and using such extract
|
BRPI0814542A2
(pt)
|
2007-07-12 |
2014-09-30 |
Tragara Pharmaceuticals Inc |
Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
|
US20090035395A1
(en)
*
|
2007-08-01 |
2009-02-05 |
Peter Koepke |
Spondias mombin l. extract and methods of extracting and using such extract
|
US8263641B2
(en)
|
2007-09-10 |
2012-09-11 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US7879369B2
(en)
*
|
2007-09-18 |
2011-02-01 |
Selvamedica, Llc |
Combretum laurifolium Mart. extract and methods of extracting and using such extract
|
CN102014631A
(zh)
|
2008-03-03 |
2011-04-13 |
泰格尔医药科技公司 |
酪氨酸激酶抑制剂
|
RU2472791C2
(ru)
|
2008-08-27 |
2013-01-20 |
КалсиМедика Инк. |
Соединения, модулирующие внутриклеточный кальций
|
NZ616673A
(en)
|
2009-02-20 |
2014-08-29 |
To Bbb Holding B V |
Glutathione-based drug delivery system
|
IL295075A
(en)
|
2009-05-06 |
2022-09-01 |
Laboratory Skin Care Inc |
Preparations for administration through the skin that include complexes of an active substance with calcium phosphate and methods of using them
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
EP2563776B1
(de)
|
2010-04-27 |
2016-06-08 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2011150156A2
(en)
*
|
2010-05-26 |
2011-12-01 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
EP2601293B1
(de)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
AU2011293201B2
(en)
|
2010-08-27 |
2015-11-05 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
EP3453762B1
(de)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
CA2882950A1
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
BR112015012295A8
(pt)
|
2012-11-28 |
2023-03-14 |
Merck Sharp & Dohme |
Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
|
CN105073746B
(zh)
|
2012-12-20 |
2017-03-22 |
默沙东公司 |
作为hdm2抑制剂的取代的咪唑并吡啶
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016144844A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of irak4 activity
|
EP3267996B1
(de)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidinhibitoren der irak4-aktivität
|
EP3268003B1
(de)
|
2015-03-12 |
2020-07-29 |
Merck Sharp & Dohme Corp. |
Thienopyrazininhibitoren der irak4-aktivität
|
WO2016177776A1
(en)
|
2015-05-04 |
2016-11-10 |
Academisch Medisch Centrum |
Biomarkers for the detection of aspirin insensitivity
|
CN104892495B
(zh)
*
|
2015-06-08 |
2017-04-26 |
青岛农业大学 |
一种新的合成含吡啶类化合物的方法
|
EP3706742B1
(de)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
EP3833668A4
(de)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
Prmt5-inhibitoren
|
EP3833667B1
(de)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
AU2020408148A1
(en)
|
2019-12-17 |
2022-06-16 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|